Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Predictive Factors of Stable Deep Molecular Response in Chronic Myeloid Leukemia Patients Treated with Imatinib Standard Dose: A Study from the Gruppo Triveneto LMC

Massimiliano Bonifacio, MD, Luigi Scaffidi, Gianni Binotto, Federico De Marchi, Elena Maino, Elisabetta Calistri, Angela Bonalumi, Luca Frison, Luciana Marin, Marta Medeot, Giovanna De Matteis, Renato Fanin, Gianpietro Semenzato, Achille Ambrosetti, Mario Tiribelli, MD

Blood (2015) 126 (23): 597.

https://doi.org/10.1182/blood.V126.23.597.597

Published: 2015

Journal Articles

Clinical Factors Predictive Of Myelofibrotic Evolutions In Patients With Essential Thrombocythemia and Polycythemia Vera

Mario Tiribelli, MD, Federico De Marchi, MD, Daniela Barraco, MD, Luciana Marin, MD, Erika Codarin, PhD, Silvia Buttignol, MD, Daniela Damiani, MD, Renato Fanin, MD

Blood (2013) 122 (21): 4082.

https://doi.org/10.1182/blood.V122.21.4082.4082

Published: 2013

Journal Articles

Imatinib-Treated CML Patients With Discordant Response Between Cytogenetic and Molecular Tests At 3 and 6 Month Timepoints Have a Reduced Probability Of Subsequent Optimal Response: A Study From The “Gruppo Triveneto LMC”

Massimiliano Bonifacio, MD, Gianni Binotto, MD, Mario Tiribelli, MD, Elisabetta Calistri, MD, Elena Maino, MD, Roberta Zanotti, MD, Luca Frison, MD, Luciana Marin, MD, Renato Fanin, MD, Gianpietro Semenzato, MD, Giovanni Pizzolo, MD

Blood (2013) 122 (21): 2732.

https://doi.org/10.1182/blood.V122.21.2732.2732

Published: 2013

Journal Articles

EUTOS Score Identifies Cases with Poor Outcome in Patients with Early Chronic Phase Chronic Myeloid Leukemia, Though Not Predictive for Optimal Response to Imatinib

Mario Tiribelli, Massimiliano Bonifacio, Elisabetta Calistri, Gianni Binotto, Elena Maino, Luciana Marin, Emanuele Guardalben, Antonio Branca, Filippo Gherlinzoni, MD, Gianpietro Semenzato, Renato Bassan, MD, Giovanni Pizzolo, MD, Renato Fanin

Blood (2012) 120 (21): 3778.

https://doi.org/10.1182/blood.V120.21.3778.3778

Published: 2012

Journal Articles

Brain Natriuretic Peptide (BNP) Level as Marker of Cardiac Function in Imatinib - Treated Chronic Myeloid Leukemia Patients: No Evidence of Cardiotoxicity of Imatinib Therapy.

Mario Tiribelli, MD, Antonio Colatutto, MD, Luciana Marin, MD, Eleonora Toffoletti, MD, Giuseppe Barbina, PhD, Ugo Qualizza, MD, Elio Tonutti, MD, Anna Candoni, MD, Marta Medeot, MD, Daniela Damiani, MD, Giorgio Morocutti, MD, Sala Pierguido, MD, Renato Fanin, MD

Blood (2007) 110 (11): 2948.

https://doi.org/10.1182/blood.V110.11.2948.2948

Published: 2007

NARROW

Predictive Factors of Stable Deep Molecular Response in Chronic Myeloid Leukemia Patients Treated with Imatinib Standard Dose: A Study from the Gruppo Triveneto LMC

Clinical Factors Predictive Of Myelofibrotic Evolutions In Patients With Essential Thrombocythemia and Polycythemia Vera

Imatinib-Treated CML Patients With Discordant Response Between Cytogenetic and Molecular Tests At 3 and 6 Month Timepoints Have a Reduced Probability Of Subsequent Optimal Response: A Study From The “Gruppo Triveneto LMC”

EUTOS Score Identifies Cases with Poor Outcome in Patients with Early Chronic Phase Chronic Myeloid Leukemia, Though Not Predictive for Optimal Response to Imatinib

Brain Natriuretic Peptide (BNP) Level as Marker of Cardiac Function in Imatinib - Treated Chronic Myeloid Leukemia Patients: No Evidence of Cardiotoxicity of Imatinib Therapy.

Email alerts

ASH Publications

American Society of Hematology

Predictive Factors of Stable Deep Molecular Response in Chronic Myeloid Leukemia Patients Treated with Imatinib Standard Dose: A Study from the Gruppo Triveneto LMC

Clinical Factors Predictive Of Myelofibrotic Evolutions In Patients With Essential Thrombocythemia and Polycythemia Vera

Imatinib-Treated CML Patients With Discordant Response Between Cytogenetic and Molecular Tests At 3 and 6 Month Timepoints Have a Reduced Probability Of Subsequent Optimal Response: A Study From The “Gruppo Triveneto LMC”

EUTOS Score Identifies Cases with Poor Outcome in Patients with Early Chronic Phase Chronic Myeloid Leukemia, Though Not Predictive for Optimal Response to Imatinib

Brain Natriuretic Peptide (BNP) Level as Marker of Cardiac Function in Imatinib - Treated Chronic Myeloid Leukemia Patients: No Evidence of Cardiotoxicity of Imatinib Therapy.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only